LBRX — LB PHARMACEUTICALS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1691082 ·
Last close
$40.30
Market Cap
$1.30B
52W High
$50.16
52W Low
$15.19
ADV30
412,520
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -62,498,000 | -59,066,000 | 453,370,000 | 215,075,000 | 35,730,000 |
| Jun 2026 | 0 | — | -53,915,000 | -51,603,000 | 361,692,000 | 283,111,000 | 29,345,000 |
| Mar 2026 | 0 | — | -22,104,000 | -19,054,000 | 393,482,000 | 320,676,000 | 14,789,000 |
| Dec 2025 | 0 | — | -13,870,000 | -11,472,000 | 312,934,000 | 250,173,000 | 11,624,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-82,395,000
Investing CF
$-44,819,000
Financing CF
$396,374,000
CapEx
$-456,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.44
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-200,185,000
Inventory
—
Receivables
—
ST Investments
$44,679,000
EBIT TTM
$-95,135,000
Pretax Income TTM
$-85,684,000
Interest Exp TTM
—
Analysts
11
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -30,404,000 | -25,205,000 | 312,934,000 | 11,624,000 | 301,310,000 | -35,208,000 |
| Dec 2024 | 0 | -64,830,000 | -63,102,000 | 33,534,000 | 128,088,000 | -94,554,000 | -53,052,000 |
| Dec 2023 | 0 | -11,376,000 | -6,275,000 | 45,657,000 | 80,130,000 | -34,473,000 | -12,094,000 |
| Dec 2022 | 0 | -2,809,000 | -14,348,000 | 21,492,000 | 50,304,000 | -28,812,000 | -2,728,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$361,692,000
Forward EPS
$-5.74
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GPCR | Structure Therapeutics Inc. | $1.30B | $18.17 | — |
| INVA | Innoviva, Inc. | $1.30B | $18.30 | — |
| MNKD | MANNKIND CORP | $1.31B | $4.07 | — |
| OCUL | OCULAR THERAPEUTIX, INC | $1.32B | $6.02 | — |
| MLYS | Mineralys Therapeutics, Inc. | $1.28B | $14.48 | — |
News headlines (Yahoo Finance, 1h cache)
LB Pharmaceuticals Inc.: Q3 Earnings Snapshot
2026-11-05 22:28 · Yahoo
LB Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-05 21:05 · Yahoo
Guggenheim names LB Pharmaceuticals a top idea ahead of pivotal trial data
2026-10-28 22:40 · Yahoo
LB Pharmaceuticals Eyes 2027 Phase III Data for LB-102 in Schizophrenia
2026-10-28 01:04 · Yahoo
LB Pharmaceuticals to Participate in Upcoming Investor Events
2026-10-15 20:05 · Yahoo
LB Pharmaceuticals Presents New Preclinical Data Supporting LB-102’s Bimodal Mechanism of Action and Highlights Ongoing Late-Stage Clinical Development Programs at the 39th ECNP Congress
2026-10-10 12:00 · Yahoo
LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)
2026-10-09 20:42 · Yahoo
LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia Treatment
2026-10-06 12:00 · Yahoo
IPO Stock LB Pharma Has Tripled In Under A Year. Is It A Takeover Target?
2026-09-09 12:00 · Yahoo
2 Reasons LB Pharmaceuticals (LBRX) Looks Pricey Following Its CFO Appointment
2026-09-04 10:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.